Evidence map›Paper›PMID 29997749›Full record

ArticleIranian journal of microbiology2018

First detection of New Delhi metallo-β-lactamases variants (NDM-1, NDM-2) among

Sarah Jehad Ismail, Suhad Saad Mahmoud

Abstract read
In one paragraph

Article in Iranian journal of microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Rapid Reversal of Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2024
    Article
  5. Article
  6. Article
  7. Phenotypic and genotypic investigation of metallo-β-lactamases inIranian journal of basic medical sciences · 2022
    Article
  8. Prevalence of multidrug-resistance andIranian journal of microbiology · 2021
    Article
  9. Polymyxin B resistance rates in carbapenem-resistantExperimental and therapeutic medicine · 2020
    Article
  10. Resistance pattern ofIranian journal of microbiology · 2020
    Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sarah Jehad IsmailDepartment of Biotechnology, University of Baghdad, AL Mansour City, Baghdad, Iraq.
Suhad Saad MahmoudDepartment of Biotechnology, University of Baghdad, AL Mansour City, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesMultidrug resistance and in particular, carbapenem resistant Gram-negative bacteria is spreading worldwide at an alarming rate. Among the clinically significant carbapenemases, the New Delhi Metallo-β-lactamase (NDM) is one of the most formidable. NDM efficiently hydrolyses β-lactams and is the last-resort among carbapenems. Hence, therapeutic options for NDM producer bacteria become restricted to a handful of antibiotics. The present study was undertaken to detect the prevalence of the MATERIALS AND

methodsA total of 100 isolates of Gram-negative bacteria obtained from various clinical samples were subjected to antibiotic susceptibility testing by the disc-diffusion method against meropenem (10 μg), imipenem (10 μg), doripenem (10 μg), polymyxin B (10 μg), colistin (10 μg), amikacin (30 μg), gentamicin (10 μg), aztreonam (30 μg), ciprofloxacin (5 μg), levofloxacin (5 μg), ofloxacin (5 μg), cefepime (30 μg), ceftazidime (30 μg), piperacillin-tazobactam (100\10 μg), tigecycline (15 μg) and tetracycline (10 μg). The results were interpreted according to the guidelines suggested by the Clinical Laboratory Standards Institute. Presence of

resultsIn the present study, four isolates of

conclusionWe are reporting emergence of the

Indexed as

blaNDM variants 1, 2Carbapenem resistanceP. aeruginosa

Identifiers

PMID29997749
PMCPMC6039455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.